Lonza Group Ag · SIX:LONN
Lonza — Investor Presentation (January 2023)
26 slides from Lonza's investor presentation, Jan 1, 2023
Slide 1: Lonza — Capturing Value in the CDMO Market
Enabling a Healthier World LONZGa Lonza — Capturing Value in the CDMO Market Pierre-Alain Ruffieux, Chief Executive Officer 1 January 2023
Slide 2: Contents
Contents Company background Our offering Set-up for success Conclusion Q&A ‘January 2023
Slide 3: A leading strategic partner to the healthcare industry
A leading strategic partner to the healthcare industry LONZa Our company in numbers >30 7 Sites across the SDGs as focus global network for sustainability ambitions cHF 5.4 bn 13% CHF 2.Qbn 24% Sales '21 Sales CAGR ‘18-21 Cumulative CAPEX over CAPEX as % of Sales ‘21 last 3 years? 31% 11% C. EBITDA
Slide 4: Supporting the molecule journey from discovery to commercialization
Supporting the molecule journey from discovery to commercialization LONZa Role of Lonza as a CDMO Contract Development Manufacturing Organization (CDMO) Trusted partner across customers’ technical journey + Development services * Process development and * Expertise in BLA? filing * Commercial drug s
Slide 5: Contents
Contents Company background Our offering Set-up for success Conclusion Q&A ‘January 2023
Slide 6: Our strong market value proposition
Our strong market value proposition LONZa Full offering creating sustainable competitive advantage © capabilities offered by Lonza Pre-clinical & Phase Il & phase | Phase il Commercial g g i) ° Seamless Network g g i) @ @ iS) 6 Trusted Quality 2 oo @ +) 1g) ) QO 6 Unmatched Breadth | smaliMotecules
Slide 7: Tailored customer offerings on global scale
1) Tailored customer offerings on global scale Lonza global Mammalian and Drug Product network LONZa Portsmouth, US Stein, CH Cambridge, UK Hayward, US 2, 2x Porrifio, ES SM: USA, CH and CN, ‘January 2023 C&G: USA, CA, NL, BE, DE, IT, SG and JP ‘CHI: USA, MX, FR, BE, JP, CN, ID and IN © Early / prec
Slide 8: Proven regulatory track record in supporting our customers
6 Proven regulatory track record in supporting our customers LONZa Regulatory filings and inspections supported by Lonza # IND and BLA filings # Regulatory Inspections? 2019-2022 2019-2022 a 44 3 expedited programs — +) 3 C&G therapies 113 brought to commercial ®@ PR & 5 —_ 20 Rest of 32 world IND F
Slide 9: Driving value in antibody drug conjugates
3) Driving value in antibody drug conjugates LONZa Integrated capabilities in bioconjugation Antibody Targets cancer cells e Lonza’s enhanced opportunity for value creation Linker — Integrated offering across divisions Joins antibody and drug +) — Strong technical capabilities from discovery to comm
Slide 10: Innovation drives unique customer offerings
Innovation drives unique customer offerings Selected examples of current innovation priorities LONZQG ‘January 2023 Inhaled mAbs Local delivery of mAbs for treatment of lung indications Reduced dose, improved patient compliance Cocoon™ + Exosomes Potential to make CGT commercially viable for large p
Slide 11: Pioneering role in high-growth mRNA CDMO market
Pioneering role in high-growth mRNA CDMO market Partnership approach to deliver end-to-end offering LONZQG ‘January 2023 Delivered Spikevax™ in record time Landmark ten-year strategic collaboration with Moderna on the mRNA platform. New product introduction on the way (beyond COVID) COVID manufactur
Slide 12: Contents
Contents Company background Our offering Set-up for success Conclusion Q&A ‘January 2023
Slide 13: Lonza is set up for success in CDMO industry
Lonza is set up for success in CDMO industry LONZGa Delivering sustainable value now and in the future Strong and stable business model Investment in future growth CHF 1.5-2.0bn' investment / * Growth investments with attractive returns and secure * Diversified business + Long-term commercial year f
Slide 14: High revenue visibility across the business
High revenue visibility across the business LONZa Drivers for revenue visibility CDMO manufacturing CDMO business strength Typical Lonza commercial contract duration e Broad-based, solid project portfolio Biologtes Po * 70% commercial business Y Up to 10 years e Full orderbook and healthy pipeline S
Slide 15: Lonza continues to invest in organic growth
Lonza continues to invest in organic growth LONZa CAPEX overview CAPEX trajectory Growth project portfolio as % of sales and in CHF # large projects! by phase; construction start date 2019 or later ~24% Return to SS ee ll Gi | 2022 under construction in ramp-up operational Growth projects offer an a
Slide 16: Large expansion securing future growth
Large expansion securing future growth LONZa Visp site evolution ‘January 2023 16
Slide 17: Long-term commitment to sustainable business practice
Long-term commitment to sustainable business practice Our ESG credentials and ambitions LONZQG 2030 Targets Baseline 20 Environmental Footprint’? -36% -36% -50% GHG emissions Energy intensity * Water intensity* intensity reduction reduction reduction® - » 100% 24% Waste intensity Renewable * reducti
Slide 18: Business fundamentals are resilient to macroeconomic environment
Business fundamentals are resilient to macroeconomic environment LONZa Our business in the current macroeconomic context Strong, stable Solid contracts Multi geography Cyclical resistant late-stage business exposure business y . 70% of CDMO sales in oly Pass-through clauses B Natural currency te Lim
Slide 19: Actions in place to mitigate most of inflation impact
Actions in place to mitigate most of inflation impact LONZa Inflation impact 2022 & 2023 2022 Headwinds Trend ‘23 Implemented Actions lective i . " Leveraging pass-through clauses Wages Sel lective increases in a high inflation markets " Consistently applying inflation clauses in contracts Time lag
Slide 20: Contents
Contents Company background Our offering Set-up for success Conclusion Q&A ‘January 2023
Slide 21: Concluding remarks
Concluding remarks Capturing value in the Healthcare market LONZGa Geographic footprint Long-term success to deliver global and driven by sustained local customer growth investments requirements in capacity and technology Broad range of technologies and capabilities to meet complex needs High custom
Slide 22: Announcing 2023 Capital Markets Day
Announcing 2023 Capital Markets Day Capital Markets Day planned for Q4 2023 Update on Divisional Update to Mid-term Combined with strategies outlook on-site visit ‘January 2023 Business Use Only
Slide 23: Contents
Contents Company background Our offering Set-up for success Conclusion Q8&A ‘January 2023
Slide 24: Q&A
Q&A Coll therapy bone marrow stem cell MJanuary 2023
Slide 25: 2s ze) c O QO QO <
2s ze) c O QO QO <
Slide 26: Additional Information and Disclaimer
Additional Information and Disclaimer LONZa Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listi